As the risks of adverse effects of warfarin and aspirin in certain patients with chronic atrial fibrillation are high, intervention with these agents should be targeted towards those who will derive most benefit. Clearer guidelines are emerging to identify those patients and to standardise current prescribing practices.
|Number of pages||3|
|Journal||The Medical journal of Australia|
|Publication status||Published - 20 May 1996|